Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584194 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 278
- Enrollment target
NCT00584194 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 278 participants.
The verdict
NCT00584194, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 278 participants
- Enrollment target
Study Summary
This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
Interventions
- BIOLOGICAL TSI-GSD 200 RVF Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2004-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00584194
The ClinicalTrials.gov registry entry for NCT00584194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TSI-GSD 200 RVF Vaccine is the first listed.
NCT00584194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00584194 about?
NCT00584194 is a clinical study titled "Safety and Immunogenicity Study of Rift Valley Fever Vaccine". This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
What is the current status of trial NCT00584194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 278 participants. The study started on 2004-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00584194?
The interventions under investigation include: TSI-GSD 200 RVF Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00584194?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.